A spinal schwannoma—also referred to as a neurinoma or neurilemmoma—is a benign peripheral nerve sheath tumor arising from Schwann cells of the spinal nerve roots. The overwhelming majority are WHO grade 1 tumors. Spinal schwannomas are among the most common intradural extramedullary neoplasms of the spinal canal and account for approximately 25–30% of spinal tumors.
Approximately 70% arise from sensory dorsal nerve roots. Most are located intradurally and extramedullary; less commonly, they are extradural or extend through the neural foramen into both the spinal canal and paraspinal soft tissues. This characteristic configuration is described as a dumbbell-shaped tumor and is often associated with widening of the neural foramen on CT imaging.
The anatomical distribution is approximately 30% cervical, 50% thoracic, and 20% lumbosacral. An important clinical association is neurofibromatosis type 2 (NF2-related schwannomatosis), in which multiple schwannomas may occur. The presence of multiple or bilateral nerve sheath tumors should therefore prompt consideration of an underlying tumor-predisposition syndrome.
Because spinal schwannomas generally grow slowly, they may remain asymptomatic for many years. When symptoms develop, their nature and severity are determined primarily by the anatomical level, tumor size, involvement of the originating nerve root, and degree of spinal cord or cauda equina compression.
Overall, the clinical presentation reflects the level of the lesion: cervical schwannomas may cause neck pain, upper-extremity radicular pain, sensory disturbance, or weakness; thoracic lesions may produce band-like truncal pain and progressive myelopathic symptoms; and lumbosacral schwannomas may cause low-back pain, radiculopathy, lower-extremity neurological deficits, and, in advanced cases, bladder or bowel dysfunction.
Contrast-enhanced MRI of the spine (imaging modality of choice): provides precise delineation of the tumor, spinal cord, nerve roots, and neural foramina.
Treatment selection depends on tumor size, anatomical location, neurological symptoms, documented growth, relationship to the spinal cord and nerve roots, patient age, comorbidities, and overall clinical condition. The following therapeutic strategies may be considered.
Radiosurgery
Stereotactic radiosurgery and stereotactic radiotherapy represent highly effective non-invasive alternatives to surgery in appropriately selected patients with spinal schwannomas. These benign, well-circumscribed nerve sheath tumors are particularly suitable for highly conformal radiation treatment, and long-term tumor-control outcomes reported for spinal schwannomas are comparable to those achieved with stereotactic radiosurgery for cranial schwannomas, including vestibular schwannoma.
Spinal schwannomas generally demonstrate excellent local response to stereotactic radiation treatment. The CyberKnife® system uses a robotically controlled linear accelerator to deliver radiation from numerous non-coplanar beam directions. This enables highly conformal shaping of the prescription isodose to the three-dimensional tumor geometry while producing a steep dose gradient toward the adjacent spinal cord and other critical neural structures.
The overwhelming majority of spinal schwannomas are benign, slow-growing WHO grade 1 tumors. Malignant peripheral nerve sheath tumors (MPNSTs) are biologically distinct malignant neoplasms and should not be regarded simply as the routine malignant transformation of a conventional spinal schwannoma. MPNSTs are rare and are strongly associated with neurofibromatosis type 1 and pre-existing plexiform neurofibromas.
Treatment is generally indicated when a spinal schwannoma causes clinically relevant symptoms—such as radicular pain, motor weakness, progressive sensory deficits, myelopathy, or bladder/bowel dysfunction—or when serial imaging demonstrates significant tumor growth. Small, asymptomatic lesions without documented progression can often initially be managed with structured MRI surveillance.
Published series report high rates of long-term local tumor control, commonly in the range of approximately 90–95% at 5 years in appropriately selected patients. Neurological improvement may occur after successful tumor control, although recovery of established neurological deficits is less predictable than after immediate microsurgical decompression in patients with clinically significant neural compression.
Yes. CyberKnife treatment is generally performed entirely on an outpatient basis, commonly in 3–5 sessions. General anesthesia and inpatient hospitalization are not required. Patients can usually leave the center shortly after completion of each treatment session.
As treatment options have become increasingly sophisticated, the choice of therapy should always be made in the context of the patient's individual clinical circumstances and personal situation. We consider it essential that patients, their families, and those supporting them fully understand the nature of the condition, the available treatment options, and the considerations relevant to an individualized treatment decision.
Together with our medical partners, we support patients throughout this process and aim to ensure that they feel comprehensively cared for from their first contact with the ERCM.
For treatment enquiries, please use our contact form. You may also contact us by telephone during our opening hours or via our social media channels. Each enquiry is reviewed individually and processed promptly.